S. Horlait

1.1k total citations
13 papers, 751 citations indexed

About

S. Horlait is a scholar working on Orthopedics and Sports Medicine, Oncology and Surgery. According to data from OpenAlex, S. Horlait has authored 13 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Orthopedics and Sports Medicine, 8 papers in Oncology and 6 papers in Surgery. Recurrent topics in S. Horlait's work include Bone health and osteoporosis research (9 papers), Bone health and treatments (7 papers) and Bone Metabolism and Diseases (6 papers). S. Horlait is often cited by papers focused on Bone health and osteoporosis research (9 papers), Bone health and treatments (7 papers) and Bone Metabolism and Diseases (6 papers). S. Horlait collaborates with scholars based in France, United States and Belgium. S. Horlait's co-authors include Christian Roux, Stefan Goemaere, Ombretta Di Munno, E. Michael Lewiecki, Li Chen, Akimitsu Miyauchi, Kurt Lippuner, Tomasz Blicharski, Paul Meisner and Paul D. Miller and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Journal of Bone and Mineral Research and Annals of the Rheumatic Diseases.

In The Last Decade

S. Horlait

13 papers receiving 725 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Horlait France	11	542	368	311	183	106	13	751
Dietrich Wenderoth United Kingdom	9	825 1.5×	649 1.8×	373 1.2×	158 0.9×	76 0.7×	13	948
E.F. Eriksen Denmark	14	522 1.0×	361 1.0×	228 0.7×	79 0.4×	71 0.7×	27	664
S. Paul United States	8	459 0.8×	476 1.3×	255 0.8×	95 0.5×	58 0.5×	14	707
Roberto Valenti Italy	9	384 0.7×	173 0.5×	207 0.7×	97 0.5×	135 1.3×	15	611
Wim H. Scheele United States	8	642 1.2×	524 1.4×	382 1.2×	128 0.7×	69 0.7×	13	905
N. Morabito Italy	17	307 0.6×	296 0.8×	159 0.5×	55 0.3×	149 1.4×	36	800
Douglas W. Axelrod United States	7	498 0.9×	465 1.3×	319 1.0×	68 0.4×	108 1.0×	13	847
J P Stapleton New Zealand	9	511 0.9×	318 0.9×	177 0.6×	114 0.6×	156 1.5×	11	815
Sanchita Agarwal United States	13	334 0.6×	159 0.4×	143 0.5×	125 0.7×	93 0.9×	42	561
Makoto Takizawa Japan	11	190 0.4×	172 0.5×	243 0.8×	144 0.8×	94 0.9×	20	515

Countries citing papers authored by S. Horlait

Since Specialization

Citations

This map shows the geographic impact of S. Horlait's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Horlait with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Horlait more than expected).

Fields of papers citing papers by S. Horlait

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Horlait. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Horlait. The network helps show where S. Horlait may publish in the future.

Co-authorship network of co-authors of S. Horlait

This figure shows the co-authorship network connecting the top 25 collaborators of S. Horlait. A scholar is included among the top collaborators of S. Horlait based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Horlait. S. Horlait is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Eriksen, Erik Fink, Roland Chapurlat, Rogely Boyce, et al.. (2020). Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial. Journal of Bone and Mineral Research. 37(1). 36–40. 29 indexed citations

Eriksen, Erik Fink, Roland Chapurlat, Rogely Boyce, et al.. (2020). Extensive modeling-based bone formation after 2 months of romosozumab treatment: Results from the FRAME clinical trial. Bone Reports. 13. 100440–100440. 4 indexed citations

Chavassieux, Pascale, Nathalie Portero-Muzy, Jean‐Paul Roux, et al.. (2019). Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial. Journal of Bone and Mineral Research. 34(4). 626–631. 11 indexed citations

Lewiecki, E. Michael, Tomasz Blicharski, Stefan Goemaere, et al.. (2018). A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 103(9). 3183–3193. 201 indexed citations

Thomas, Thierry, et al.. (2012). Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice. Osteoporosis International. 24(1). 263–269. 30 indexed citations

Roux, Carel W. le, et al.. (2007). Assessment of non-vertebral fracture risk in postmenopausal women. Annals of the Rheumatic Diseases. 66(7). 931–935. 23 indexed citations

Fechtenbaum, J., Claire Cropet, S. Kolta, et al.. (2005). The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporosis International. 16(12). 2175–2179. 95 indexed citations

Roux, Christian, Ego Seeman, Richard Eastell, et al.. (2004). Efficacy of risedronate on clinical vertebral fractures within six months. Current Medical Research and Opinion. 20(4). 433–439. 128 indexed citations

Roux, Christian, Pasquale Oriente, Roland Laan, et al.. (1998). Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss. The Journal of Clinical Endocrinology & Metabolism. 83(4). 1128–1133. 122 indexed citations

10.

Pouillès, J. M., Florence Trémollières, Christian Roux, et al.. (1997). Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporosis International. 7(3). 213–218. 32 indexed citations

11.

Duranteau, Lise, P. Chanson, Alain Lavoinne, et al.. (1991). Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine‐resistant prolactinomas. Clinical Endocrinology. 34(1). 25–29. 48 indexed citations

12.

Khalfallah, Y., et al.. (1990). Effects of a New Prolactin Inhibitor, CV 205–502, in the Treatment of Human Macroprolactinomas*. The Journal of Clinical Endocrinology & Metabolism. 71(2). 354–359. 18 indexed citations

13.

Horlait, S., P. Chappuis, A Moynot, et al.. (1988). Cortical v Trabecular Bone Aluminum in Dialyzed Patients. American Journal of Kidney Diseases. 12(3). 220–226. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact